tiprankstipranks
Trending News
More News >
Ligand Pharma (LGND)
NASDAQ:LGND
US Market

Ligand Pharma (LGND) Income Statement

Compare
830 Followers

Ligand Pharma Income Statement

Last quarter (Q3 2025), Ligand Pharma's total revenue was $115.46M, an increase of 122.85% from the same quarter last year. In Q3, Ligand Pharma's net income was $117.27M. See Ligand Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 167.13M$ 131.31M$ 196.25M$ 241.54M$ 163.56M
Gross Profit
$ 156.06M$ 96.27M$ 143.42M$ 179.37M$ 133.14M
Operating Expenses
$ 178.66M$ 84.32M$ 140.38M$ 75.52M$ 95.64M
Depreciation and Amortization
$ 35.24M$ 36.52M$ 43.39M$ 50.95M$ 27.97M
EBITDA
$ 40.79M$ 100.84M$ 81.20M$ 142.77M$ 56.67M
Operating Income
$ -22.61M$ 11.94M$ 3.04M$ 103.85M$ 37.50M
Other Income/Expenses
$ 25.12M$ 51.72M$ 32.97M$ -31.65M$ -36.21M
Pretax Income
$ 2.52M$ 63.66M$ 36.01M$ 72.20M$ 1.29M
Net Income
$ -4.03M$ 52.15M$ -33.36M$ 57.14M$ -2.98M
Per Share Metrics
Basic EPS
$ -0.22$ 3.02$ -1.98$ 3.46$ -0.18
Diluted EPS
$ -0.22$ 2.94$ -1.98$ 3.34$ -0.18
Weighted Average Shares Outstanding
18.29M 17.30M 16.87M 16.63M 16.18M
Weighted Average Shares Outstanding (Diluted)
18.29M 17.76M 16.87M 17.25M 16.18M
Currency in USD

Ligand Pharma Earnings and Revenue History